Fresenius Group Overview

Investors

Fresenius Investment Highlights

 

  • Diversified revenue and earnings base with four strong business segments

  • Leading positions in non-cyclical markets with predictable growth

  • Industry-leading organic growth in all business segments

  • Strong earnings performance and cash flow generation

  • Attractive shareholder returns

  • Prudent financial management

 

"2018 was not an easy year, and yet it was another successful one for Fresenius. We have further developed and enhanced our medical offering, while once again increasing both sales and earnings. 2019 will be a year of investment in growth areas such as home dialysis, biosimilars and new hospital services and therapies. Our goal is to provide even better treatment for even more patients as the basis for continued, strong growth – which is also reflected in our healthy mid-term growth targets."
(Stephan Sturm, Chairman of the Management Board)

News

  • Brief News
    Fresenius Helios becomes medical partner at Rafa Nadal Academy

    Quirónsalud, the Spanish hospitals unit of Fresenius Helios, has become the Rafa Nadal Academy’s official medical partner. The sports academy of Spain’s Rafael Nadal (nickname “Rafa”), a top international tennis player with 17 Grand Slam tournament victories, offers regular schooling combined with special athletic training for promising young tennis players. As medical partner, Quirónsalud will take responsibility for the athletes’ healthcare, from nutritional advice through to medical treatment. 

    April 23, 2019Fresenius Helios
    Brief News
    Fresenius Kabi launches Adenosine in prefilled syringes in the U.S.

    Adenosine, a drug used in critical care settings, is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes. Fresenius Kabi now offers the broadest portfolio of Adenosine Injection.

    April 09, 2019Fresenius Kabi
  • Brief News
    Fresenius Kabi receives European Commission approval for adalimumab biosimilar IDACIO®

    The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

    April 03, 2019Fresenius Kabi
    Brief News
    Fresenius Helios and Marburger Bund agree on collective labor agreement

    Helios Germany and the doctors' union Marburger Bund have agreed on a collective labor agreement for about 5,400 physicians in 34 Helios hospitals. It applies to the hospitals included in the Helios Group collective labor agreement. With effect from 1 January 2019, the base salary will increase by 2.5 percent. A further increase of 2.5 percent will follow on January 1, 2020. Salaries will thus increase by a total of 5 percent. This is in line with Fresenius Group's expectations.

    March 19, 2019Fresenius Helios
  • Brief News
    Fresenius Helios holds topping-out ceremony for new hospital building in Wiesbaden

    Fresenius Helios held the topping-out ceremony today for the new main building at Helios HSK hospital in the German city of Wiesbaden, near Frankfurt. The seven-story structure, with almost 100,000 square meters (about 1 million square feet) of floor space, is being erected beside the existing clinic. It will have 22 operating rooms, about 1,000 beds, and a design that significantly reduces distances and waiting times for patients. Helios is investing about €200 million in the new building, while the state of Hesse is contributing €68 million. Completion is scheduled for 2021.

    March 15, 2019Fresenius Helios
    Fresenius reports 15th consecutive record year – Significant investments into medium-term growth in FY/18 and FY/19 – Healthy medium-term growth targets
    February 20, 2019Fresenius
  • Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Methocarbamol Injection is the newest addition to the company´s anesthesia and analgesia portfolio.

    February 12, 2019Fresenius Kabi
    Brief News
    Fresenius Kabi receives positive CHMP opinion for MSB11022, a biosimilar candidate of adalimumab

    Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
    *Humira® is a registered trademark of AbbVie Biotechnology Ltd.

    February 01, 2019Fresenius Kabi
  • Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Leucovorin Calcium is the newest addition to the company’s large oncology portfolio.

    January 29, 2019Fresenius Kabi
    Brief News
    Fresenius Vamed adds new resort to network in Austria

    VAMED Vitality World has taken over operation of a health resort in Austria’s Styria state. Operating under the new name of Spa Resort Styria in the town of Bad Waltersdorf, near Graz, the resort will offer health tourism for adults. Fresenius Vamed is the market leader in Austria, with about 3.2 million annual visitors to the company’s eight thermal spas and health resorts.

    January 14, 2019Fresenius Vamed
  • Fresenius successfully places €1.0 billion in notes

    Fresenius today successfully placed notes in two tranches with an aggregate volume of €1.0 billion.

    January 10, 2019Fresenius
    Brief News
    Fresenius wins award for compensatory time account calculator

    Fresenius has been awarded the HR Excellence Award 2018 in the Compensation & Benefits category for the global healthcare group’s compensatory time account calculator. This calculator enables employees to quickly and transparently access information on time off that they have banked, options to take leave for continuing education or to care for family members, and possible early retirement. The HR Excellence Awards have been presented by Human Resources Manager magazine since 2012 to recognize outstanding projects in personnel management.

    December 14, 2018Fresenius
  • Brief News
    Fresenius Kabi launches Omegaven® in the U.S.

    Omegaven® is an intravenous lipid emulsion that provides calories and fatty acids. In the U.S. it is indicated for pediatric patients with parenteral nutrition-associated cholestasis, or PNAC. With Omegaven® Fresenius Kabi provides the first and only FDA-approved fish oil lipid emulsion for this condition.

    December 10, 2018Fresenius Kabi
    Brief News
    PWC proposed as auditor for 2020

    The Supervisory Board of Fresenius SE & Co. KGaA has decided to propose PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as the auditor for the financial year 2020. The shareholders will decide on the appointment at the Annual General Meeting in 2020. New regulations provide for a regular rotation of the auditor, so Fresenius was not able to extend the existing mandate of KPMG AG Wirtschaftsprüfungsgesellschaft.

    December 10, 2018Fresenius
  • Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019
    December 06, 2018Fresenius
    Brief News
    Fresenius Kabi receives FDA Drug Shortage Assistance Award

    Fresenius Kabi has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA). The FDA recognized the role Fresenius Kabi played in helping mitigate a shortage of IV saline, specifically Sodium Chloride Injection USP, 0.9% in bags. The shortage was caused last year by supply disruptions at manufacturers affected by Hurricane Maria.  The hurricane devastated Puerto Rico, where many companies produce medicines for U.S. hospitals.

    December 03, 2018Fresenius Kabi
  • Brief News
    Fresenius Vamed wins awards for spa and wellness facilities

    VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2018” at the World Spa Awards. Four VAMED Vitality World facilities – Geinberg5 Private Villas, Aqua Dome Therme Längenfeld, Therme Laa Hotel & Spa, all in Austria, and Aquaworld Resort Budapest in the Hungarian capital – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria and Hungary.

    November 26, 2018Fresenius Vamed
    Brief News
    Fresenius training programs among the best in Germany

    A recent study places Fresenius among the top 500 companies in terms of career training programs in Germany. Criteria used for judgement were the quality of supervision, in-house training, company engagement, success rate and innovative teaching methods. The companies were rated by the business magazine Capital and the internet portal, ausbildung.de. Fresenius received a best possible five-star rating for its on-the-job training and dual-studies, a combination of theory and on-the-job training, programs. The company trains more than 4,000 apprentices and dual-studies interns.

    November 19, 2018Fresenius
  • Fresenius in Q3/18 with continued strong Group earnings growth in constant currency
    October 30, 2018Fresenius
    Brief News
    Fresenius Helios acquires private hospital operator in Colombia, expanding presence in Latin America

    Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has acquired Clínica Medellín and entered the attractive private hospital market in Colombia. Clínica Medellín operates two centrally located hospitals in Medellín, a major city of 2.5 million people. The two facilities have a total of about 185 beds. The total investment for Clínica Medellín is more than €50 million. Following Quirónsalud's entry into Peru last year, this is another step in strengthening the company’s presence in Latin America’s growing and consolidating hospital markets. Fresenius Helios expects the transaction to close in Q1 2019, pending anti-trust and regulatory clearance.

    October 30, 2018Fresenius Helios
  • Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Arsenic Trioxide Injection is the newest addition to the company’s oncology portfolio.

    October 26, 2018Fresenius Kabi
    Brief News
    Fresenius Kabi launches IV drug in the US

    Fresenius Kabi HYDROmorphone Hydrochloride injection is a new offering for the company, expanding its analgesia and anesthesia portfolio. It is available in six single-dose vial presentations.

    October 24, 2018Fresenius Kabi
  • Brief News
    Fresenius Kabi launches Palonosetron in prefilled syringe in the U.S.

    Palonosetron Hydrochloride Injection is now available in the U.S. and is the newest product in the company’s Simplist™ prefilled syringe portfolio.  It is an antiemetic used to manage chemotherapy-induced nausea and vomiting. Fresenius Kabi is the first company to offer U.S. customers Palonosetron Hydrochloride in a ready-to-administer syringe.

    October 22, 2018Fresenius Kabi
    Brief News
    Fresenius Kabi launches Heparin in freeflex® container in the U.S.

    Fresenius Kabi has launched Heparin Sodium injection in ready-to-administer non-DEHP freeflex® bags, expanding the company’s critical care portfolio. Fresenius Kabi offers a comprehensive portfolio of Heparin Sodium in the U.S. with multiple vial presentations, a pre-filled syringe and bag presentations.

    October 19, 2018Fresenius Kabi
  • Fresenius Kabi reaches a global agreement with AbbVie
    October 18, 2018Fresenius Kabi
    Fresenius confirms and narrows Group guidance for FY/18 and publishes preliminary results for Q3/18
    October 16, 2018Fresenius
  • Brief News
    Fresenius Kabi opens compounding center in Canada

    Fresenius Kabi has opened a new state-of-the-art compounding center in Canada. It involves an investment of 11 million Canadian dollars (more than €7 million), and the new site expands the company’s presence in Mississauga, Ontario. Fresenius Kabi is responding to increasing demand for large batches of compounded medications for patients in Canadian hospitals, and the 35,000-square-foot (3,300-square-meter) compounding center has the capacity to expand. The new facility is expected to employ 70 people by 2022.

    October 16, 2018Fresenius Kabi
    Brief News
    Fresenius Kabi biosimilar candidate meets primary endpoints in the two pivotal clinical studies

    Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11455, a biosimilar candidate for Neulasta® (pegfilgrastim), has met its primary endpoints in the two pivotal clinical studies. For more information please see the website of Fresenius Kabi.

    October 09, 2018Fresenius Kabi
  • Brief News
    2019 DRG inflator for German hospitals set at 2.65%

    The price increase for hospital services in Germany has been set at 2.65% for 2019. This is in line with the level of past years.

    September 17, 2018Fresenius Helios
    Brief News
    Fresenius Helios opens new hospital in Cordoba

    Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, is opening a new hospital in Cordoba today. The company now has six hospitals in Andalusia, Spain’s most southernly autonomous community. The six-floor, approximately 25,000-square-meter (269,000-square-foot) facility includes 100 large private patient rooms, a 24-hour emergency department, seven operating rooms and a surgical outpatient clinic. Quirónsalud has invested €50 million in the new hospital.    

    September 17, 2018Fresenius Helios
Disclaimer All News

Library

All Financial Reports

Information & Order Service

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time.

Please enter your first name.
Please enter your last name.
Please enter your company.
Please enter your department.
Please enter your function.
Please enter your street.
Please enter your postal code and city.
Please enter your e-mail address.

Please send me via email


Do you have other questions or need any more information?
Please send us a message:

To unsubscribe to these services, please send a brief e-mail to ir-fre@fresenius.com or call +49 (0) 6172 608-2470. 

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com


Contact
Visit us

Fresenius SE & Co. KGaA

We use cookies to create cross-page statistical evaluations that we use to tailor our web pages to meet your needs. By clicking on "Yes", you agree to the use of these cookies. You will find more detailed information about these cookies and the associated data processing as well as the possibility of revocation in our data protection policy. To select individual types of cookies, please use the cookie settings.

Learn more
Yes No